Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amgen Inc. (AMGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer and a component of the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen uses SEC filings to report financial results, material events and other information relevant to shareholders.
Amgen’s Form 8-K filings illustrate how the company communicates quarterly performance. For example, 8-K reports dated August 5, 2025 and November 4, 2025 describe second and third quarter earnings press releases, including unaudited results of operations and financial position. These filings also explain Amgen’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and Free Cash Flow. The company outlines which acquisition-related expenses, restructuring charges and other items are excluded from GAAP results and how the related tax effects are calculated.
On this page, users can review Amgen’s current and historical SEC documents, including Forms 10-K and 10-Q when available, 8-Ks for earnings and other material events, and additional filings that may address debt offerings, governance matters or other disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly understand topics such as segment performance, non-GAAP adjustments, liquidity metrics and risk factor discussions without reading every page.
The filings page also surfaces information relevant to questions about AMGN stock, such as how management describes its financial performance, what non-GAAP metrics it emphasizes and how it discusses acquisition-related charges and restructuring initiatives. Real-time updates from EDGAR, combined with AI-generated overviews, allow investors to follow new Amgen filings as they appear and to place each document in the context of the company’s broader financial and regulatory history.
Amgen Inc. (AMGN) Form 144 notice reports a proposed sale of 1,267 shares of common stock through Raymond James & Associates on 08/20/2025 with an aggregate market value of $372,908.81. The shares were acquired from the issuer on 03/18/2024 via RSE/DEU grants and paid in cash. The filing lists 538,360,000 shares outstanding. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Amgen director S. Omar Ishrak reported the acquisition of 121.4308 shares of Amgen common stock on 08/08/2025 via vested restricted stock units under the Amgen Inc. 2009 Director Incentive Program. The transaction is shown at a $0 price, reflecting issuance of shares upon vesting, and the Form 4 was signed on 08/09/2025.
The filing reports 6,241.9302 shares beneficially owned following the transaction, held directly. The reported shares include 291 Dividend Equivalents credited to vested but deferred RSUs and payable in shares under a dividend reinvestment arrangement. The document identifies the reporting person as a director of Amgen (AMGN).
On 08/08/2025 Amgen director Charles M. Holley reported the immediate vesting of restricted stock units (RSUs) granted under Amgen's Director Incentive Program. The vested RSUs were converted to common stock on a one-for-one basis and recorded as an acquisition (transaction code A) with a reported price of $0.
Following the reported transaction Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust. The filing also shows 1,294 Dividend Equivalents credited to vested but deferred RSUs, which are payable in shares one-for-one with cash for any fractional share amounts.
Michael V. Drake, a director of Amgen Inc. (AMGN), reported the vesting and conversion of Restricted Stock Units into 121.4308 shares on 08/08/2025. The vested RSUs convert one-for-one into common stock and were reported at a purchase price of $0, reflecting compensation rather than an open-market trade. After the transaction his direct beneficial ownership is reported as 4,699.0291 shares. The reported amount includes 227 Dividend Equivalents credited on vested-but-deferred RSUs that are paid in shares under the Director Incentive Program and the Amgen Inc. 2009 Equity Incentive Plan.